Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Scientists hope new test could help contain meningitis outbreaks

Published 08/28/2016, 11:44 AM
Updated 08/28/2016, 11:44 AM
Scientists hope new test could help contain meningitis outbreaks

By Umberto Bacchi

LONDON (Thomson Reuters Foundation) - A test has been developed that could help diagnose bacterial infections including meningitis in minutes, but it could take several years before a cheap testing device is available to developing countries, scientists said on Wednesday.

The new test could save lives, allow treatment of disease - which is difficult to diagnose - to start much sooner and reduce the risk of life-changing after effects, an international team of researchers led by Imperial College London said.

"We would very much hope this could become something cheap enough to be applied even in resource poor regions," Imperial College Professor Michael Levin told the Thomson Reuters Foundation.

Currently the only test available for meningitis, whose symptoms include a high fever, headaches and vomiting, is expensive and takes more than 48 hours, Levin said.

A study led by the pediatrician shows that bacterial infections can be distinguished from other causes of fever.

The research revealed that two genes in white blood cells become active only in case of bacterial infections, according to the study published in the JAMA medical journal.

Researchers said a cheap pin-prick blood test able to accurately identify bacterial infections in less than one hour could be developed within five years.

"If this works... (we) could have an accurate test in situations such as in sub-Saharan Africa where there are epidemics of meningitis and accurate testing using the current methodologies is really difficult," study co-author Dr Jethro Herberg said.

Meningitis is common across Africa's so-called "meningitis belt" from Senegal to Ethiopia. An outbreak of meningitis killed at least 90 people in Niger this year, according to medical charity Médecins Sans Frontières (MSF).

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

A 2009 outbreak caused more than 80,000 cases, while some 20,000 people died in another epidemic, in 1996–1997.

Meningitis, which is prevalent in children and elderly people, can be treated with antibiotics, but 10 percent to 15 percent of patients die and up to 19 percent of survivors have long-term disabilities, including brain damage and limb amputations.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.